13,113 Shares in Agilon Health, Inc. $AGL Acquired by Tidal Investments LLC

Tidal Investments LLC purchased a new position in shares of Agilon Health, Inc. (NYSE:AGL) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 13,113 shares of the company’s stock, valued at approximately $1,405,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. North Peak Capital Management LLC increased its holdings in shares of Agilon Health by 10.8% during the fourth quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock valued at $26,267,000 after purchasing an additional 3,715,460 shares during the period. Rubicon Founders LLC acquired a new stake in Agilon Health in the second quarter worth about $11,290,448. Bank of New York Mellon Corp lifted its holdings in Agilon Health by 9.5% in the second quarter. Bank of New York Mellon Corp now owns 35,336 shares of the company’s stock worth $3,787,000 after purchasing an additional 3,074 shares during the period. UBS Group AG grew its position in Agilon Health by 250.7% in the 4th quarter. UBS Group AG now owns 3,395,366 shares of the company’s stock valued at $2,339,000 after buying an additional 2,427,136 shares in the last quarter. Finally, Great Lakes Advisors LLC bought a new position in Agilon Health in the 2nd quarter valued at about $702,000.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Truist Financial set a $112.00 target price on shares of Agilon Health and gave the company a “hold” rating in a research note on Thursday, August 6th. Royal Bank Of Canada set a $125.00 price target on shares of Agilon Health in a research note on Tuesday. JPMorgan Chase & Co. boosted their target price on Agilon Health from $31.00 to $85.00 and gave the stock an “underweight” rating in a report on Monday, August 24th. Sanford C. Bernstein upgraded Agilon Health from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $86.00 to $125.00 in a research report on Tuesday. Finally, Benchmark reaffirmed a “buy” rating and set a $140.00 price target (up from $95.00) on shares of Agilon Health in a research note on Thursday, August 6th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Agilon Health has an average rating of “Hold” and an average price target of $102.25.

Agilon Health Stock Down 0.2%

Shares of Agilon Health stock opened at $88.95 on Friday. The stock’s fifty day moving average is $97.64 and its 200-day moving average is $71.79. The firm has a market capitalization of $1.49 billion, a PE ratio of -6.23 and a beta of 3.02. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.07. Agilon Health, Inc. has a 12-month low of $7.48 and a 12-month high of $133.04.

Agilon Health (NYSE:AGL) last released its quarterly earnings results on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.90. The business had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.45 billion. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%. Equities analysts anticipate that Agilon Health, Inc. will post -2.9 earnings per share for the current year.

Agilon Health Company Profile

Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company focuses primarily on patients enrolled in Medicare Advantage plans and works with physician groups to coordinate care, improve outcomes and manage healthcare costs.

Agilon provides physicians with technology, analytics, operational support and clinical resources designed to help them manage the health of defined patient populations.